BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22297111)

  • 1. Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity.
    Sundar BG; Bailey TR; Dunn D; Hostetler GA; Chatterjee S; Bacon ER; Yue C; Schweizer D; Aimone LD; Gruner JA; Lyons J; Raddatz R; Lesur B
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1546-9. PubMed ID: 22297111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.
    Hudkins RL; Aimone LD; Bailey TR; Bendesky RJ; Dandu RR; Dunn D; Gruner JA; Josef KA; Lin YG; Lyons J; Marcy VR; Mathiasen JR; Sundar BG; Tao M; Zulli AL; Raddatz R; Bacon ER
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5493-7. PubMed ID: 21782432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.
    Zulli AL; Aimone LD; Mathiasen JR; Gruner JA; Raddatz R; Bacon ER; Hudkins RL
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2807-10. PubMed ID: 22450133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.
    Hudkins RL; Zulli AL; Dandu Rr; Tao M; Josef KA; Aimone LD; Haltiwanger RC; Huang Z; Lyons JA; Mathiasen JR; Raddatz R; Gruner JA
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1504-9. PubMed ID: 22290075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
    Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
    Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.
    Hudkins RL; Aimone LD; Dandu RR; Dunn D; Gruner JA; Huang Z; Josef KA; Lyons JA; Mathiasen JR; Tao M; Zulli AL; Raddatz R
    Bioorg Med Chem Lett; 2012 Jan; 22(1):194-8. PubMed ID: 22142542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H
    Nirogi R; Shinde A; Mohammed AR; Badange RK; Reballi V; Bandyala TR; Saraf SK; Bojja K; Manchineella S; Achanta PK; Kandukuri KK; Subramanian R; Benade V; Palacharla RC; Jayarajan P; Pandey S; Jasti V
    J Med Chem; 2019 Feb; 62(3):1203-1217. PubMed ID: 30629436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.
    Nagase T; Mizutani T; Ishikawa S; Sekino E; Sasaki T; Fujimura T; Ito S; Mitobe Y; Miyamoto Y; Yoshimoto R; Tanaka T; Ishihara A; Takenaga N; Tokita S; Fukami T; Sato N
    J Med Chem; 2008 Aug; 51(15):4780-9. PubMed ID: 18598020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonists.
    Tao M; Aimone LD; Gruner JA; Mathiasen JR; Huang Z; Lyons J; Raddatz R; Hudkins RL
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1073-7. PubMed ID: 22197136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel steroidal histamine H
    Ledneczki I; Tapolcsányi P; Gábor E; Éles J; Greiner I; Schmidt É; Némethy Z; Kedves RS; Balázs O; Román V; Lévay G; Mahó S
    Bioorg Med Chem Lett; 2017 Oct; 27(19):4525-4530. PubMed ID: 28888822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists.
    Roche O; Nettekoven M; Vifian W; Sarmiento RM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4377-9. PubMed ID: 18606542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
    Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
    J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
    Nirogi R; Benade V; Daripelli S; Subramanian R; Kamuju V; Bhyrapuneni G; Muddana NR; Mekala VR; Petlu S; Jayarajan P; Badange R; Shinde A; Jasti V
    Psychopharmacology (Berl); 2021 Jun; 238(6):1495-1511. PubMed ID: 33550481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.
    Rodríguez Sarmiento RM; Nettekoven MH; Taylor S; Plancher JM; Richter H; Roche O
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4495-500. PubMed ID: 19524437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity.
    Dandu RR; Gruner JA; Mathiasen JR; Aimone LD; Hostetler G; Benfield C; Bendesky RJ; Marcy VR; Raddatz R; Hudkins RL
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6362-5. PubMed ID: 21944855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
    Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
    Hudkins RL; Gruner JA; Raddatz R; Mathiasen JR; Aimone LD; Marino MJ; Bacon ER; Williams M; Ator MA
    Neuropharmacology; 2016 Jul; 106():37-45. PubMed ID: 26400408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists.
    Del Tredici AL; Ma JN; Piu F; Burstein ES
    J Pharmacol Exp Ther; 2014 Jan; 348(1):116-24. PubMed ID: 24204014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.
    Jitsuoka M; Tsukahara D; Ito S; Tanaka T; Takenaga N; Tokita S; Sato N
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5101-6. PubMed ID: 18768318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.